Asarina Pharma AB
Developed Sepranolone for neurological disorders like Tourette's, OCD, and menstrual migraine.
ASAP | ST
Overview
Corporate Details
- ISIN(s):
- SE0011641794
- LEI:
- 549300PP1GKOHKYQ6K97
- Country:
- Sweden
- Address:
- Fogdevreten 2, 171 65 Solna
- Website:
- https://asarinapharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Asarina Pharma AB was a Swedish clinical-stage biotechnology company focused on developing its proprietary compound, Sepranolone. The company's primary objective was to create treatments for stress- and compulsion-related neurological disorders by modulating the effects of the neurosteroid Allopregnanolone. Its therapeutic targets included Tourette Syndrome, Obsessive-Compulsive Disorder (OCD), and menstrual migraine. Asarina Pharma was the first to synthesize and patent Sepranolone as a pharmaceutical formulation. In February 2025, the company sold its Sepranolone assets. Following a shareholder resolution in April 2025, the company is proceeding with a voluntary liquidation, effective July 2025.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Asarina Pharma AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Asarina Pharma AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
